Fly News Breaks for May 20, 2019
May 20, 2019 | 07:24 EDT
Barclays analyst Geoff Meacham says that despite the 18% decline of Regeneron Pharmaceuticals shares year-to-date, he remains bearish on the name with an Underweight rating and $315 price target. The analyst cites Eylea concentration risk and the near/long-term competitive threat in wet age-related macular degeneration. Pricing and/or share erosion in wet AMD from brolucizumab or DARPin could yield worse than consensus expectations, Meacham tells investors in a research note.
News For REGN From the Last 2 Days
Jun 24, 2019 | 08:26 EDT
Advanced Endovascular & Coronary Intervention Global Summit (C3) will be held in Orlando, FL on June 23-26.